Table 2 Patient data stratified by ΔScvO2
|  | Low ScvO2 fluctuation (ΔScvO2 < 10%) (n = 36) | High ScvO2 fluctuation (ΔScvO2 ≥ 10%) (n = 17) | p |
|---|---|---|---|
Preoperative factors | |||
 Age | 70 (60–77) | 69 (66–74) | 0.742 |
 Sex (male/female) | 27: 9 | 13: 4 | 0.597 |
 BMI | 22.3 (20.5–24.6) | 22.4 (19.9–25.2) | 0.874 |
 ASA (1: 2: 3) | 1: 31: 4 | 0: 17: 0 | 0.382 |
 Hypertension (%) | 11/36 (30.6) | 4/17 (23.5) | 0.426 |
 Hyperlipidemia (%) | 3/36 (8.3) | 0/17 (0) | 0.305 |
 Diabetes (%) | 7/36 (19.4) | 5/17 (29.4) | 0.318 |
 Primary disease (HCC: others) | 23: 13 | 6: 11 | 0.051 |
 PTPE (%) | 1/36 (2.8) | 3/17 (17.6) | 0.092 |
 History of hepatitis virus infection (HBV: HCV: no) | 5: 4: 27 | 1: 3: 13 | 0.597 |
 Child–Pugh classification (A: B: C) | 35: 1: 0 | 17: 0: 0 | 0.679 |
 Liver damage classification (A: B: C) | 30: 6: 0 | 16: 1: 0 | 0.269 |
 White blood cell (/μL) | 5260 (4405–6193) | 5450 (4460–6560) | 0.804 |
 Platelet (× 104/μL) | 18.6 (14.6–24.0) | 22.2 (17.5–23.7) | 0.423 |
 Prothrombin activity (%) | 103 (97–113) | 101 (94–115) | 0.600 |
 Aspartate transaminase (IU/L) | 28 (22–40) | 24 (22–25) | 0.088 |
 Alanine transaminase (IU/L) | 23 (15–33) | 19 (16–23) | 0.340 |
 Total bilirubin (mg/dL) | 0.7 (0.6–1.1) | 0.9 (0.5–1.2) | 0.625 |
 Alkaline phosphatase (IU/L) | 226 (201–289) | 230 (182–263) | 0.542 |
 γ-Glutamyltranspeptidase (IU/L) | 45 (25–89) | 45 (25–64) | 0.790 |
 Albumin (g/dL) | 4.2 (3.9–4.4) | 4.2 (4.0–4.4) | 0.863 |
 Cholinesterase (IU/L) | 279 (240–322) | 260 (224–289) | 0.607 |
 Total cholesterol (mg/dL) | 193 (162–217) | 177 (148–200) | 0.261 |
 C-reactive protein (mg/dL) | 0.09 (0.04–0.25) | 0.16 (0.05–0.65) | 0.417 |
 HbA1c (%) | 6.1 (5.5–6.5) | 5.9 (5.6–6.0) | 0.498 |
 ICG R15 (%) | 18.1 (12.0–24.6) | 13.3 (11.3–16.5) | 0.091 |
 NLR | 2.85 (1.75–4.08) | 3.70 (2.43–4.15) | 0.073 |
 PLR | 135.3 (108.8–235.2) | 193.8 (146.6–254.1) | 0.086 |
 LMR | 3.43 (2.55–4.32) | 3.04 (2.53–4.97) | 0.844 |
 CLR | 8.33 (4.20–17.96) | 11.85 (5.07–82.25) | 0.303 |
 CAR | 0.022 (0.010–0.059) | 0.039 (0.013–0.151) | 0.423 |
Intraoperative factors | |||
 Operative method (minor: major) | 34: 2 | 12: 5 | 0.017 |
 laparotomy: laparoscopy | 15: 21 | 13: 4 | 0.018 |
 Operation time (min) | 294 (253–350) | 301 (261–397) | 0.317 |
 Intraoperative bleeding (mL) | 105 (56–383) | 435 (50–660) | 0.093 |
 Urine volume (mL) | 255 (110–398) | 250 (140–372) | 0.985 |
 Transfusion (%) | 3/36 (8.3) | 2/17 (11.8) | 0.520 |
 Crystalloid fluid volume (mL) | 1850 (1450–2585) | 2200 (1850–2800) | 0.185 |
 Intraoperative in–out balance (mL/kg/h) | 6.83 (5.24–8.37) | 6.56 (5.77–7.10) | 0.939 |
 Total Pringle maneuver time (min) | 90 (60–115) | 75 (56–90) | 0.175 |
 Hepatectomy time (min) | 118 (91–164) | 109 (76–154) | 0.667 |
Postoperative factors | |||
 Max white blood cell (/μL) | 10,780 (8440–12410) | 8970 (7130–11010) | 0.148 |
 Min platelet (× 104/μL) | 13.1 (9.4–17.0) | 14.7 (12.0–17.0) | 0.640 |
 Min prothrombin activity (%) | 71 (61–84) | 66 (53–74) | 0.114 |
 Max aspartate transaminase (IU/L) | 210 (152–404) | 358 (224–597) | 0.072 |
 Max alanine transaminase (IU/L) | 206 (123–378) | 350 (228–467) | 0.057 |
 Max total bilirubin (mg/dL) | 1.2 (1.0–1.7) | 1.7 (1.2–2.1) | 0.079 |
 Min albumin (g/dL) | 3.1 (2.8–3.3) | 2.8 (2.7–3.0) | 0.092 |
 Min cholinesterase (IU/L) | 179 (160–216) | 160 (124–172) | 0.036 |
 Max C-reactive protein (mg/dL) | 8.40 (5.94–11.94) | 9.47 (7.85–12.39) | 0.542 |
 Complications of CDC grade IIIa or higher (%) | 0/36 (0) | 2/17 (11.8) | 0.099 |
 CCI | 0 (0–14.4) | 20.9 (0–24.2) | 0.043 |
 Postoperative length of stay (day) | 9 (8–12) | 11 (9–14) | 0.135 |
 Surgical site infection (%) | 3/36 (8.3) | 2/17 (11.8) | 0.520 |
 Bile leakage (%) | 0/36 (0) | 1/17 (5.9) | 0.321 |
 Pleural effusion (%) | 3/36 (8.3) | 5/17 (29.4) | 0.059 |
 Ascites (%) | 4/36 (11.1) | 3/17 (17.6) | 0.398 |
 Pneumonia (%) | 0/36 (0) | 1/17 (5.9) | 0.321 |
 Diarrhea (%) | 2/36 (5.6) | 1/17 (5.9) | 0.695 |
 Delayed gastric emptying (%) | 0/36 (0) | 2/17 (11.8) | 0.099 |